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Abstract Benzimidazole derivatives of 5,6-dichlorobenz-
imidazole 1-b-D-ribofuranoside (DRB) comprise the
important class of protein kinase CK2 inhibitors. Depend-
ing on the structure, benzimidazoles inhibit CK2 with
different selectivity and potency. Besides CK2, the com-
pounds can inhibit, with similar activity, other classical
eukaryotic protein kinases (e.g. PIM, DYRK, and PKD).
The present results show that a majority of the most
common CK2 inhibitors can affect the atypical kinase Rio1
in a nanomolar range. Kinetic data confirmed the mode of
action of benzimidazoles as typical ATP-competitive
inhibitors. In contrast to toyocamycin—the first discovered
small-molecule inhibitor of Rio1—the most potent repre-
sentative of benzimidazoles TIBI (IC50 = 0.09 lM,
Ki = 0.05 lM) does not influence the oligomeric state of
the Rio1 kinase. Docking studies revealed that TIBI can
occupy the ATP-binding site of Rio1 in a manner similar to
toyocamycin, and enhances the thermostability of the
enzyme.
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Introduction
Protein kinases play important roles in key cellular pro-
cesses, including the cell cycle, metabolism, and cell death
[1, 2]. The protein kinase superfamily, with 518 members,
comprises one of the largest protein superfamilies identified
in the human genome [3]. In addition to their key roles in
cell physiology, about half of protein kinases are linked to
pathological states, including cancer [4, 5]. This fact makes
kinases attractive targets for therapeutic intervention.
One such kinase therapeutic target is probably the most
pleiotropic protein kinase, CK2. It phosphorylates more than
300 protein substrates and thus remarkably increases the
level of total protein phosphorylation in the cell [6, 7].
Interestingly, the enzyme is constitutively active, and the
mode of its on/off mechanism is unknown [7, 8]. The ple-
thora of cellular partners makes protein kinase CK2 engaged
in a majority of cellular processes, both physiological, such
as the cell cycle, and pathological ones, e.g. viral infection
or cancer development [9]. Elevated expression and activity
levels of CK2 have been reported in many human patholo-
gies, including cancer cells (reviewed in [10]).
Benzimidazole derivatives represent the biggest family
of ATP-competitive inhibitors of protein kinase CK2, with
a scaffold derived from the 5,6-dichloro-1-(b-D-ribofura-
nosyl)benzimidazole (DRB) molecule [11]. Starting from
this molecule, the structure of the inhibitors has been
optimized to better fit in the ATP-binding pocket [12]. In
this respect, the most successful commercially available
benzimidazole CK2 inhibitors are TBB, TBI, and DMAT
[13]. Benzimidazole derivatives effectively inhibit both
native and recombinant CK2 activity in vitro and in cell
culture showing proapoptotic properties [14, 15]. Although
benzimidazole derivatives are potent inhibitors of CK2,
TBB, TBI, and even the most selective DMAT show
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activity towards several other kinases, such as PIM,
DYRK, or PKD [13].
The protein kinase superfamily includes 40 members
that are classified as atypical protein kinases. One such
enzyme is the Rio1 kinase, the founding member of the
RIO family that also comprises Rio2, Rio3, and RioB
[16, 17]. Rio1 is involved in ribosome biogenesis, cell
cycle progression, and chromosome maintenance [18–20].
Studies on yeast revealed that Rio1 is a non-ribosomal
factor that is essential for the processing of 20 S pre-rRNA
to 18 S rRNA, a component of the 40 S subunit [21, 22].
Little is known about the physiological role of Rio1-me-
diated phosphorylation, cellular protein substrates of the
enzyme, and the physiological role of Rio1 autophospho-
rylation. Although the possible role of Rio1 in pathogenesis
is not well established in comparison to many other kina-
ses, it was reported that the enzyme is upregulated in colon
cancer, and there is a direct link between deregulation of
ribosome biogenesis and tumour development [23]. In
other studies, Read and coworkers showed that the kinases
Rio1 and Rio2 are overexpressed in glioblastoma cells in
an Akt-dependent manner and promote tumorigenesis [24].
Toyocamycin was the first identified small-molecule
inhibitor of Rio1, showing mixed inhibition. This mode of
action of toyocamycin results from its dual activity towards
the Rio1 kinase. On the one hand, toyocamycin acts as an
ATP-competitive inhibitor, and on the other hand, it sta-
bilizes the less catalytically active oligomeric isoform of
the Rio1 kinase [25]. Recently, several pyridine caffeic
acid benzyl amides (CABA) have been identified as a novel
molecular probes of the Rio1 following the ATP-compet-
itive inhibition mode [26].
Here we present a series of benzimidazole CK2 inhibi-
tors as novel synthetic small-molecule inhibitors of the
Rio1 kinase. We analysed the kinetic data of Rio1
autophosphorylation in the presence of the most active
compound TIBI, with respect to the inhibition model. In
order to verify the influence of TIBI on the thermostability
of human Rio1, we determined the melting temperature of
the enzyme in the presence and absence of the inhibitor.
We also employed size-exclusion chromatography to val-
idate whether TIBI is able to affect the oligomeric state of
Rio1. Moreover, computational studies were used in order
to calculate possible kinase–ligand complexes.
Materials and methods
Reagents and benzimidazole CK2 inhibitors
All reagents were purchased from Sigma-Aldrich. 4,5,6,7-
Tetrabromo-2-azabenzimidazole, (TBB), 2-dimethy-
lamino-4,5,6,7-tetrabromobenzimidazole (DMAT), and
toyocamycin were purchased from Sigma-Aldrich. CX-
4945 (Silmitasertib) was purchased from APEXBIO. All
the other benzimidazoles studied were synthesized in our




















Recombinant human protein kinase GST-CK2a was pro-
duced in bacteria and purified as described elsewhere [32].
The plasmid carrying the gene encoding human protein
kinase Rio1 (residues 143–494) was kindly gifted by Pro-
fessor Nicole LaRonde—LeBlanc (University of Maryland,
USA). Human recombinant kinase Rio1 containing resi-
dues 134–494 was expressed and purified as previously
reported with a few modifications [33].
In the case of CK2, the phosphorylation reactions were
conducted at 37 C for 5 min in 50 ll samples each con-
taining 1 pmol of human recombinant CK2a, 10 lg of
ribosomal P2B protein as a substrate, and an appropriate
concentration of the tested benzimidazole (0.01–50 lM).
The reaction buffer contained 20 lM [c-32P]ATP (specific
radioactivity 300–1000 cpm/pmol), 15 mM Mg2?, 20 mM
Tris–HCl pH 7.5, and 6 mM 2-mercaptoethanol.
In order to determine the autophosphorylation of human
Rio1, the enzyme was incubated at 37 C for 15 min in
50 ll samples each containing 1 pmol of human recom-
binant Rio1 and an appropriate concentration of tested
compound (0.01–50 lM). The reaction buffer contained
0.5 lM ATP, [c-32P]ATP (specific radioactivity
300–1000 cpm/pmol), 50 mM NaCl, 10 mM Mg2?,
50 mM Tris–HCl pH 7.5, and 6 mM 2-mercaptoethanol.
In order to determine the Km of Rio1 for ATP, Rio1 was
incubated for 5 min in the presence of increasing concen-
trations of ATP (0.001–1 lM) in a reaction buffer
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containing 50 mM NaCl, 10 mM Mg2?, 50 mM Tris–HCl
pH 7.5, 6 mM 2-mercaptoethanol, and 1 lCi of [c-32P]
ATP. Additionally, the same protocol was followed with
the addition of TIBI to the reaction mixture at a concen-
tration of 0.01, 0.05, and 0.1 lM. The use of such low
concentrations of ATP in reaction mixtures was optimal for
Rio1, and resulted from the inhibition of Rio1 activity at
ATP concentration greater than 1 lM [25, 26].
The phosphorylation was terminated by addition of
SDS/PAGE sample buffer, and proteins were resolved by
electrophoresis, followed by Coomassie Brilliant Blue
staining. The gels were dried and 32P-labelled bands of
P2B and Rio1 were excised from the gel, and radioactivity
was determined in a scintillation counter (MicroBeta,
Perkin Elmer) by Cerenkov counting.
Kinetic data were obtained using enzyme preparations
from three purification batches.
All experiments were performed in triplicate.
IC50, Ki, Km, and Vmax values were calculated using
GraphPad Prism (version 4.0) software.
Thermofluor assay
The procedure was performed according to the protocol
described elsewhere with a few modifications [25]. 10-ll
reactions containing 50 mM NaCl, 10 mM Mg2?, 50 mM
Tris–HCl pH 7.5, 1 mg/ml hRio1 or hCK2a, and 100 lM
TIBI or 5% DMSO (control) were incubated at 4 C for
30 min. 10 ll of the SYPRO Orange dye was then added to
the reactions. The samples were heated from 4 to 98 C at a
rate of 0.2 per second using a thermal cycler (CFX 1000,
Bio-Rad). The changes in fluorescence intensity were
measured as the temperature increased. Melting tempera-
tures (Tm) of hRio1 and CK2 in the presence and absence
of TIBI were calculated using Bio-Rad software. The
experiment was performed in duplicate.
Size-exclusion chromatography
The glass column (200/10 mm) filled with the Sephadex
G-200 medium (GE Healthcare) was equilibrated with a
buffer containing 10 mM Tris, pH 7.5, 150 mM NaCl, and
6 mM b-mercaptoethanol. In order to calibrate the column,
four proteins, namely b-amylase (200 kDa), alcohol
dehydrogenase (150 kDa), bovine serum albumin
(67 kDa), and ovalbumin (43 kDa), were separately loaded
onto the column. 100-ll samples containing 2 mg/ml
hRio1 diluted in the equilibration buffer in the presence or
absence (control) of 100 lM TIBI were then loaded onto
the column. The chromatography was performed at a flow
rate 0.2 ml/min using the FPLC system AKTA Purifier 10
(GE Healthcare), and runs were monitored by OD280.
Computational studies
For molecular docking, we selected the X-ray structure of
CK2 in complex with ANP (PDB ID: 3NSZ) and Rio1 in
complex with ADP (PDB ID: 4OTP) as target proteins for
the initial docking studies. All Mg2? ions were removed in
the 3NSZ and 4OTP experimental structures as well as all
sulphates, co-solvents, water molecules, and original
ligands. The structures were then minimized using
YASARA Energy Minimization Server [34]. Autodock
Tools v1.5.6 (The Scripps Research Institute) was used for
charging the proteins as well as ligands. Docking calcula-
tions were performed with Autodock Vina v1.1.2 (The
Scripps Research Institute) under default conditions [35].
During the docking calculations, all the protein residues
were fixed and only the inhibitor atoms were allowed to
move. Visualization of the binding site complexed with the
docked ligand was performed by Maestro Suite and
PyMOL v1.2 (Schro¨dinger) software.
Results and discussion
Benzimidazole inhibitors of protein kinase CK2
suppress the autophosphorylation of an atypical
human kinase Rio1
Halogenated benzimidazoles are widely reported as CK2
inhibitors that (i) downregulate both native and recombi-
nant protein kinases CK2 from various sources [36], (ii)
can discriminate between different isoforms of the enzyme
in vitro [31, 37], (iii) induce apoptosis in many cancer cell
lines [38, 39], and (iv) can inhibit other classical eukaryotic
protein kinases with different potency [13]. Our results
show that the atypical protein kinase (the most stable form
of Rio1 containing residues 134–494) is susceptible to
benzimidazole inhibitors of CK2 (Table 1). With the
exception of TDBB, TCI, and TBB, the tested compounds
suppress the autophosphorylation of the Rio1 kinase in a
nanomolar range. Although TBB inhibits CK2 ca. 10 times
more strongly (IC50 = 0.19 lM, Ki = 0.081 lM) than
Rio1 (IC50 = 1.74 lM, Ki = 0.983 lM), the atypical
kinase belongs, together with Pim1 and Pim3, to the most
sensitive kinases to TBB action [13]. TCI displays the least
efficacy towards the two tested kinases, which is consistent
with previous reports showing that chloride derivatives of
benzimidazoles are not as efficient CK2 inhibitors as other
halogenated derivatives [36]. The majority of the other
nanomolar inhibitors behave more similarly against CK2
and Rio1 with a slight advantage of the former one. The
inhibition of CK2 by TI-2Am was ca. sixfold stronger than
that of Rio1. In turn, K92 induced fourfold stronger inhi-
bition of CK2 than that of Rio1, and in the case of 1Me-
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Table 1 IC50 and Ki determinations for benzimidazole derivatives against protein kinases Rio1 and CK2
Inhibitor Structure IC50 (lM) ± SD Ki (lM) ± SD
Rio1 CK2 Rio1 CK2
TIBI 0.09 ± 0.005 0.083 ± 0.003 0.05 ± 0.002 0.035 ± 0.001
K92 0.19 ± 0.011 0.066 ± 0.003 0.1 ± 0.004 0.025 ± 0.001
DMAT 0.19 ± 0.009 0.19 ± 0.008 0.1 ± 0,003 0.081 ± 0.003
TI-2Am 0.23 ± 0.01 0.050 ± 0.002 0.13 ± 0.005 0.021 ± 0.001
TIdiMe 0.24 ± 0.008 0.20 ± 0.006 0.135 ± 0.005 0.085 ± 0.003
K95 0.29 ± 0.009 0.30 ± 0.009 0.164 ± 0.007 0.128 ± 0.005
TBI 0.33 ± 0.007 0.44 ± 0.01 0.186 ± 0.009 0.188 ± 0.007
1Me-DMAT 0.61 ± 0.02 0.39 ± 0.012 0,344 ± 0.011 0.167 ± 0,009
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Table 1 continued
Inhibitor Structure IC50 (lM) ± SD Ki (lM) ± SD
Rio1 CK2 Rio1 CK2
TBSB 0.65 ± 0.03 0.33 ± 0.013 0.367 ± 0.012 0.141 ± 0.005
TBTS 0.69 ± 0.,2 0.60 ± 0.03 0.39 ± 0.011 0.257 ± 0.009
TBB 1.74 ± 0.05 0.19 ± 0,007 0.983 ± 0.03 0.081 ± 0.002
TCI 1.9 ± 0.07 9.7 ± 0.3 1.07 ± 0.04 4.15 ± 0.1
TDBB 2.17 ± 0.06 1.51 ± 0.04 1.226 ± 0.03 0.647 ± 0.014
Reference compounds
Toyocamycin 3.66 ± 0.09 54.78 ± 1.9 2.068 ± 0.07 23.47 ± 0.8
CX-4945 0.37 ± 0.011 0.005 ± 0.0001 0.209 ± 0.008 0.002 ± 0.00007
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DMAT and TBSB, the inhibition of CK2 was twofold
stronger than that of Rio1. The other compounds showed
almost the same efficacy towards both kinases, and TIBI
with IC50 = 0.09 lM and Ki = 0.05 lM appeared to be
the most potent inhibitor of Rio1. We observed that higher
potency towards the atypical kinase was shown by the
iodine derivatives of benzimidazole (IC50 between 0.09
and 0.24 lM, Ki values between 0.05 and 0.135 lM) than
by the bromide derivatives (IC50 between 0.19 and
2.17 lM, Ki values between 0.1 and 1.226 lM), with no
significant changes caused by the addition of methyl (K92,
TIdiMe) or amino groups (TI-2Am). One of the most
potent inhibitors of Rio1 is the commercially available
DMAT (IC50 = 0.19 lM, Ki = 0.1 lM), which appeared
to be not as selective towards CK2 (IC50 = 0.19 lM,
Ki = 0.081 lM) as TBB, which is consistent with data
presented previously by Pagano and coworkers [13].
Selected benzimidazoles appeared to be more potent (up to
ca. 20-fold) toward Rio1 than the first identified inhibitor of
Rio1, toyocamycin (IC50 = 3.66 lM, Ki = 2.068 lM), or
20- to 120-fold stronger in comparison to the recently
developed Rio1 probes - pyridine caffeic acid benzyl
amides (CABA) (IC50 from 3.8 to 23.7 lM). Thus,
derivatives of halogenated benzimidazoles may constitute a
novel class of inhibitors of protein kinase Rio1 [25, 26].
In order to make complete representation of the link
between Rio1 and CK2, two reference compounds toy-
ocamycin and CX-4945 were also used [25, 40]. Protein
kinase CK2 was quite refractory (IC50 = 55 lM,
Ki = 23.48 lM) to toyocamycin, the first small-molecule
inhibitor of kinase Rio1, while the atypical kinase showed
sensitivity (IC50 = 0.37 lM, Ki = 0.209 lM) towards
CX-4945—the most potent inhibitor of the protein kinase
CK2, currently being in clinical trials. Although the
nanomolar range of the IC50 value may suggest intriguing
potency of CX-4945 towards Rio1, the compound is a
much more potent inhibitor of several other kinases, with
CK2 on the top [40–42].
TIBI as an ATP-competitive inhibitor of Rio1,
and its influence on oligomerization of the enzyme
In order to determine whether the well-known ATP-com-
petitive inhibitors of protein kinase CK2 act in the same
mode towards Rio1, we determined the steady-state kinetic
parameters for the kinase (Km for ATP and Vmax of Rio1) in
the presence and absence of TIBI. To calculate these
parameters, the assay of Rio1 autophosphorylation reaction
was used and the level of phosphate (P-32) incorporated
into Rio1 was measured. We observed that Km for ATP
began to rise with increasing TIBI concentrations, starting
with 0.65 lM (at 0 lM TIBI - control) to 1.07 lM at
100 lM TIBI (Fig. 1a). Simultaneously, we did not notice
any shift in the Vmax value remaining at the same level of
0.09 pmol/sec with the increasing TIBI concentration. To
confirm the ATP-competitive nature of the TIBI action, we
measured the IC50 values of TIBI for three different ATP
concentrations. As expected, the parameter showed a
dependence of the ATP content; IC50 for TIBI increased
with the increasing ATP concentrations as follows: 46, 61,
and 101 nM at 0.01, 0.1, and 1 lM of ATP, respectively
(Fig. 1b). Such low ATP concentrations used in this
experiment result from the sensitivity of the kinase Rio1 to
Fig. 1 Steady-state analyses of Rio1. a Km for ATP and Vmax of Rio1
at the increasing concentration of TIBI. b IC50 determinations for
TIBI against Rio1 at different ATP concentrations. c Size-exclusion
chromatography plots for Rio1 with (black line) and without (grey
line) TIBI. The positions of molecular weight standards (kDa) are
indicated with arrows
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ATP concentration higher than 1 lM [25, 26]. Since the
results obtained correspond to the linear relationship
between IC50 and ATP described in the Cheng and Prusoff
equation, TIBI and most probably the other tested benz-
imidazoles act as strict ATP-competitive inhibitors of the
atypical kinase Rio1 [43].
Based on the data from the size-exclusion chromatog-
raphy, we observed that human Rio1 (aa 134–494) can
exist in two isoforms, i.e. a monomer (49 kDa) and a
dominant tetramer (185 kDa) (Fig. 1c). Similar observa-
tion by Kiburu and LaRonde revealed that unphosphory-
lated human and archaeal Rio1 forms higher order
oligomers, while phosphorylation promotes monomeriza-
tion [25]. In contrast to the recently evaluated inhibitors of
the Rio1 kinase (toyocamycin, CABA), TIBI seems not to
function as an allosteric inhibitor of Rio1 promoting less
active oligomeric states of the kinase [26]. In the case of
hRio1 treated with TIBI, we did not observe any changes in
the monomer–tetramer equilibrium, compared with the
intact enzyme. This observation is consistent with the
kinetic data indicating an ATP-competitive mode of TIBI
and thus benzimidazole action in Rio1 inhibition.
TIBI can occupy the ATP-binding site and enhances
the thermostability of protein kinase Rio1
In order to rationalize the biological results discussed
above, docking studies were performed with the TIBI
compound and toyocamycin. The docking calculations of
TIBI and Rio1 rendered a common pose for the benzo-
triazole moiety within the ATP-binding site in kinase
CK2 described in resolved crystal structures (Fig. 2b)
[30]. The main core of the inhibitor is lodged deep in the
binding pocket establishing Van der Waals interactions
with the side chains of Leu331, Ile340, Ile186, Val194,
Ile280, Pro286, Pro265, Ala206, and Met277 within the
adenine-binding site. In turn, the diazole ring is oriented
towards the hydrophilic area composed of side chains of
Lys208, Glu250, and Asp341. Similar results were
obtained for toyocamycin. The main adenosine ring
occupies the same space as the benzotriazole ring of
TIBI, while the charged sugar ring faces the bulk solvent
at the entrance to the ATP-binding pocket, where the
side chains of Ser287, Asp341, and Ans329 are located
(Fig. 2a).
The thermal shift assay revealed that TIBI—the novel
benzimidazole inhibitor of human Rio1—significantly
enhanced the thermostability of the kinase (Fig. 3a). We
observed a shift of 10 C in the melting temperature (Tm)
of bound Rio1 (68.8 C) in comparison to the unbound
enzyme (58.8 C). The results obtained correspond to data
presented by Kiburu and LaRonde, who reported a shift of
12.1 C in Tm in the case of the human Rio1 bound to
toyocamycin [25]. Simultaneously, we compared the Rio1
with CK2 with respect to the TIBI-mediated changes in the
thermostability of proteins. On the one hand, as it is
described above, TIBI shows similar potency towards
CK2a and Rio1, which reflects the IC50 values, i.e. 0.083
and 0.09 lM, respectively. On the other hand, a shift of
20 C in the melting temperature (Tm) of TIBI-bound
CK2a (78.8 C) in comparison to the unbound enzyme
(58.8 C) was observed (Fig. 3b). Thus, TIBI when bound
to CK2a stabilizes structure of the enzyme to a greater
degree than in the case of Rio1.
The link between atypical kinase Rio1 and CK2
Our results provide another relationship between the two
kinases. CK2-mediated phosphorylation of yeast Rio1 and
its influence on upregulation of the enzyme were reported
[44]. The authors showed that Rio1 interacts preferentially
with CK2a‘ and phosphorylation of Rio1 promotes cell
proliferation. Thus, the similar susceptibility of the two
kinases to benzimidazoles creates another cross-link
between the enzymes, and creates an additional condition
Fig. 2 Docked binding mode obtained with Autodock Vina for
a TIBI (purple) and toyocamycin (green) in Rio1, b TIBI in Rio1
(yellow carbons and green cartoon) and CK2 (grey carbons and
aquamarine cartoon). (Color figure online)
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for designing novel benzimidazole-based inhibitors of
CK2.
Although it is widely reported that halogenated benz-
imidazoles inhibit protein kinase CK2 and induce apopto-
sis, the molecular mechanism by which these chemicals
function in cells has not been systematically explored.
Duncan and coworkers revealed that structurally related
TBB, TBI, and DMAT had unique biological properties,
suggesting differences in inhibitor specificity [45]. Our
results suggest that proapoptotic benzimidazoles may,
among many other cellular events, cause disturbances in
Rio1 activity and, consequently, in ribosome biogenesis,
and these events may contribute to benzimidazole-medi-
ated programmed cell death. Koronkiewicz and coworkers
showed proapoptotic activity of TIBI in the promyelocytic
leukemia cell line HL-60 [39]. Taking the above into
consideration, the promising findings presented here need
to be extended with the use of cell lines in order to assess
the influence of TIBI on endogenous Rio1.
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